Vasopharm Sees Path Forward For Traumatic Brain Injury Drug
Ronopterin Misses Primary Endpoint In NOSTRA III Trial
Executive Summary
Vasopharm’s ronopterin (VAS203) missed its primary endpoint in the Phase III NOSTRA III study in patients with traumatic brain injury, but further analyses point to a significant clinical benefit when the inducible NOS inhibitor is given within 12 hours of trauma, suggesting a role for the compound in the condition.